NASDAQ:CTOR

Citius Oncology Q1 2026 Earnings Results & Report

Citius Oncology logo
$0.56 +0.01 (+1.79%)
Closing price 04:00 PM Eastern
Extended Trading
$0.55 -0.01 (-0.97%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Citius Oncology met analyst earnings expectations and missed on revenue in its Q1 2026 results, released February 13, 2026. The company reported EPS of -$0.06 versus the -$0.06 consensus estimate, while revenue of $3.94 million fell short of the $4.37 million estimate by $428.89 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

Citius Oncology EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.06
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
0 of last 5 quarters

Citius Oncology Revenue Results

Actual Revenue
$3.94 million
Expected Revenue
$4.37 million
Beat/Miss
Missed by -$428.89 thousand
YoY Revenue Growth
N/A

Upcoming Earnings

Citius Oncology's Q4 2026 earnings is estimated for Thursday, December 17, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, December 23, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Citius Oncology Q1 2026 Earnings FAQ

Citius Oncology (NASDAQ:CTOR) reported earnings of -$0.06 per share for Q1 2026, matching the consensus estimate of -$0.06. The report was announced on Friday, February 13, 2026.

Citius Oncology reported revenue of $3.94 million for Q1 2026, against a consensus estimate of $4.37 million.

Citius Oncology's next earnings date is estimated for Thursday, December 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Citius Oncology on the company's earnings history page.

Citius Oncology Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Citius Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Citius Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Citius Oncology and other key companies, straight to your email.

About Citius Oncology

Citius Oncology (NASDAQ:CTOR) is a biopharmaceutical company focused on developing and commercializing oncology therapies. Its lead product is LYMPHIR (denileukin diftitox-cxdl), an immunotherapy approved in the United States for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

LYMPHIR targets cells expressing the interleukin-2 receptor and is intended to treat certain forms of CTCL, a rare non-Hodgkin lymphoma that affects the skin. The company’s commercial activities are centered on making the therapy available to eligible patients in the U.S.

Citius Oncology became a publicly traded company following a business combination involving Citius Pharmaceuticals’ oncology subsidiary and TenX Keane Acquisition. Leonard Mazur, a co-founder and longtime executive of Citius Pharmaceuticals, has served as Citius Oncology’s chief executive officer.

View Citius Oncology Profile